The asset-backed primary is bracing for another busy week after 16 issuers priced more than US$14.8bn last week, while the RMBS sector is expecting a number of jumbo deals. Over in the ECM, primary ...

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

and other perks or benefits you may receive when opening or maintaining a high-yield savings account. Although we strive to maintain up-to-date information, savings interest rates and incentives ...

Bob Haegele is a freelance personal finance writer. He specializes in topics such as credit cards, investing, and banking. Bob holds a degree from Marquette University in Milwaukee, Wisconsin.

However, several high-yield savings accounts (HYSAs) still pay annual percentage yields (APYs) of up to 4.50%, even after these federal rate cuts. This compares to the 0.01% APYs some of the ...

Telus pays a quarterly dividend of $0.402 per share, translating into a high yield of about 8% based on the closing price of $20.18 (as of January 21, 2025). Thanks to its ability to consistently ...

Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reiterated by stock ... a 52 week low of $1.42 and a 52 week high of $15.10. Emergent BioSolutions (NYSE ...

Tuesday, H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The endorsement comes after the company announced a significant contract ...

Tuesday, H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The endorsement comes after the company announced a significant ...

The table below provides a snapshot of their recent ratings ... analysts unveil insights for Emergent BioSolutions, presenting an average target of $14.25, a high estimate of $15.00, and a ...